Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Next steps in the development of CXCR4 inhibitors for mycosis fungoides

Lilach Moyal • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Plerixafor

Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, outlines the next steps in the development of CXCR4 inhibitors for the treatment of mycosis fungoides (MF). At the moment, research is focused on pre-clinical studies examining the mechanism of action of these agents and explore potential therapeutic candidates including plerixafor and other novel CXCR4 inhibitors. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Lilach Moyal

1:08
The CXCR4/CXCL12 axis as a potential therapeutic target in mycosis fungoides
Lilach Moyal • 15 Oct 2021
0:57
The effect of CXCR4 inhibition on malignant cells
Lilach Moyal • 15 Oct 2021
1:43
Potential clinical applications of CXCR4 antagonists in cancer
Lilach Moyal • 15 Oct 2021
0:47
Mechanism of CXCR4 inhibition
Lilach Moyal • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals